Predicted binding sites were acquired by utilizing computational tools such as AlphaFold 3 and HDOCK2.4 for structure prediction and docking interaction analysis, respectively. Then, the GrASP Web Server was used to confirm these predicted binding sites, resulting in one out of the fifteen antibodies being chosen due to its strong binding affinity. This study's results reveal essential information on the role of creating novel CAR T-cell therapy, which targets IL-13Rα2 receptors and may be able to treat patients with GBM who would not otherwise be able to get treatment.